兩種新型檢測方法可以檢測腺苷脫氨酶結合蛋白，在膿毒血癥與急性腎功能衰竭起病之前，這種蛋白在尿樣本中的水平已經升高。 這些檢測方法是做為膿毒敗血癥與急性腎功能衰竭的新型診斷/治療方案而研發的，只做為研究之用。檢測膿毒敗血癥的方法叫做ABP-26，檢測急性腎功能衰竭的方法叫做Nephroscreen。設計這些檢測方法的目的是為了比當前使用的診斷方法更早的檢測并相應使用預防性治療措施。這些檢測方法都是美國Signet實驗室研制的。 Signet的其它免疫病理診斷產品包括：P504，檢測前列腺癌與前列腺活檢標本中新生物病變的抗體輔助診斷方法；Acuity小鼠:小鼠聚合體檢測系統，使用單克隆或者多克隆抗體檢測小鼠或者大鼠組織的檢測系統。Acutiy讓研究者減少抗體用量、提高染色強度以及消除背景來降低成本， 在過去的一年中，Signet開發了一系列單克隆抗體、多克隆抗體以及酶聯免疫吸附試劑盒用于檢測癌癥、感染性疾病以及神經退行性疾病。公司近期宣布擴大生產線，用于診斷性檢測方法和抗體來檢測與治療嚴重的疾病。 Signet公司總裁兼首席執行光Richard Gill醫生解釋說：“我們的目標是繼續創造新試劑與診斷方法，來預測疾病出現、研發治療方法，做為臨床實踐的戰勝疾病的可靠武器。” New Assays for Sepsis Two new assays measure levels of adenosine deaminase-binding protein (ADBP), which has been shown to rise in urine samples prior to onset of both sepsis and acute renal failure. The assays were developed as a new diagnostic/therapeutic regime for sepsis and acute renal failure (SARF) and both are for research use only. The assay for sepsis is called ABP-26, and the assay for acute renal failure is called Nephroscreen. They are designed to enable detection and the use of preventive therapy far earlier than current diagnostic regimes. The assays were developed by Signet Laboratories (Dedham, MA, USA). Other new immunopathology products from Signet include P504, an antibody aiding the diagnosis of prostate cancer and neoplastic changes in prostate biopsies; and the Acuity mouse-on-mouse polymer detection system, a system for use with monoclonal and polyclonal antibodies on mouse or rate tissue. Acuity provides cost savings by enabling researchers to use less antibody, while increasing staining intensity and eliminating background. Over the past year, Signet has launched an array of monoclonal and polyclonal antibodies and enzyme-linked immunosorbent assay (ELISA) kits for cancer, infectious disease, and neurodegenerative disease. The company has recently announced the expansion of its product line of diagnostic assays and antibodies for detecting and treating critical disease states. “Our goal is to continue to create new reagents and diagnostics that predict emergence of disease, and develop therapies as reliable preventive weapons against disease in clinical setting,” explained Dr. Richard Gill, president and CEO of Signet Labs.